Description

MK-2866, also known as Ostarine, is a non-steroidal selective androgen receptor modulator (SARM) designed to selectively bind to androgen receptors in skeletal muscle and bone. Its tissue-selective activity allows it to promote anabolic effects without significantly affecting organs such as the prostate or liver, minimizing androgenic side effects.

Research on Ostarine has focused on its ability to stimulate protein synthesis, increase lean body mass, and prevent muscle wasting in both healthy and catabolic conditions. It has been investigated for applications in muscle atrophy, osteoporosis, and rehabilitation following injury. Unlike traditional anabolic steroids, MK-2866 does not convert to estrogen or DHT, offering a more controlled hormonal profile in research settings. Its favorable safety margin and oral bioavailability make it a frequently studied compound in trials exploring anabolic therapies with reduced systemic risks.